Prachi Borude, Genea Edwards, Chad Walesky, Feng Li, Xiaochao Ma, Bo Kong, Grace L. Guo, Udayan Apte – 22 June 2012 – Farnesoid X receptor (FXR), the primary bile acid–sensing nuclear receptor, also plays a role in the stimulation of liver regeneration. Whole body deletion of FXR results in significant inhibition of liver regeneration after partial hepatectomy (PHX). FXR is expressed in the liver and intestines, and recent reports indicate that FXR regulates a distinct set of genes in a tissue‐specific manner.

Xuefeng Xia, Dongju Jung, Paul Webb, Aijun Zhang, Bin Zhang, Lifei Li, Stephen D. Ayers, Chiara Gabbi, Yoshiyuki Ueno, Jan‐Åke Gustafsson, Gianfranco Alpini, David D. Moore, Gene D. LeSage – 22 June 2012 – Nuclear receptors (NRs) play crucial roles in the regulation of hepatic cholesterol synthesis, metabolism, and conversion to bile acids, but their actions in cholangiocytes have not been examined. In this study, we investigated the roles of NRs in cholangiocyte physiology and cholesterol metabolism and flux.

Allan Tsung, Gary W. Nace, David A. Geller – 22 June 2012

Emmanuel A. Tsochatzis, Jaime Bosch, Andrew K. Burroughs – 22 June 2012 – Cirrhosis is a major health problem, being the 5th cause of death in the U.K. and 12th in the U.S., but 4th in the 45 to 54 age group. Until recently cirrhosis was considered a single and terminal disease stage, with an inevitably poor prognosis. However, it is now clear that 1‐year mortality can range from 1% in early cirrhosis to 57% in decompensated disease. As the only treatment for advanced cirrhosis is liver transplantation, what is urgently needed is strategies to prevent transition to decompensated stages.

Wangta Liu, Jim‐Ray Chen, Chih‐Hao Hsu, Yen‐Hsing Li, Yi‐Meng Chen, Chien‐Yuan Lin, Shin‐Jie Huang, Zen‐Kuei Chang, Yen‐Chun Chen, Chi‐Hsueh Lin, Hong‐Yi Gong, Ching‐Chun Lin, Koichi Kawakami, Jen‐Leih Wu – 22 June 2012 – The mechanisms that mediate the initiation and development of intrahepatic cholangiocarcinoma (ICC) associated with hepatitis B and C virus (HBV and HCV, respectively) infection remain largely unclear.

Laura Mensa, Sofia Perez‐del‐Pulgar, Xavier Forns – 22 June 2012

Jung Pyo Lee, Hyuk Yong Kwon, Ji In Park, Nam‐Joon Yi, Kyung‐Suk Suh, Hae Won Lee, Myounghee Kim, Yun Kyu Oh, Chun Soo Lim, Yon Su Kim – 19 June 2012 – Liver transplantation (LT) is the treatment of choice for hepatorenal syndrome (HRS). However, the clinical benefits of living donor liver transplantation (LDLT) are not yet well established. We, therefore, investigated the outcomes of patients with HRS who underwent LDLT and patients with HRS who received transplants from deceased donors.

Chung‐Mau Lo – 19 June 2012

Milan J. Sonneveld, Willem P. Brouwer, Harry L.A. Janssen – 18 June 2012

Bernhard Jäger, Andreas Drolz, Barbara Michl, Peter Schellongowski, Andja Bojic, Miriam Nikfardjam, Christian Zauner, Gottfried Heinz, Michael Trauner, Valentin Fuhrmann – 18 June 2012 – Hypoxic hepatitis (HH) is the most frequent cause of acute liver injury in critically ill patients. No clinical data exist about new onset of jaundice in patients with HH. This study aimed to evaluate the incidence and clinical effect of jaundice in critically ill patients with HH. Two hundred and six consecutive patients with HH were screened for the development of jaundice during the course of HH.